Systems biology reveals BDNF's role in enhancing b lymphopoiesis in human bone marrow, highlighting potential therapeutic strategies.
B-cell aplasia impairs the immune response to cancer, infections and vaccines. However, no B-cell accelerator is available in the clinic to date. Here, we utilized a system biology approach to discover drivers for B lymphopoiesis in the human Bone Marrow (BM). By integrating scRNA-seq data analyses with intercellular communication mapping, we created an initial list of putative drivers emanating from the BM microenvironment and interacting with nascent B lymphocytes. We further intersected our findings with clinical B-cell depletion studies and developmental conditions pointing at age-impaired B lymphopoiesis. These funneling procedures enabled identification of putative top drivers on which we performed progenitor BM cells scRNA-seq stimulation assays, demonstrating their ability to upregulate immune developmental pathways within early B-cells. Finally, we succesfully validated BDNF, a neurotrophin, as a B-cell accelerator in in-vitro culture. Our systems-biology methodology paves the way towards identification of additional human hematopoiesis drivers and immune recovery and functionality.
No takes yet. Share an insight, caveat, or question.
Nevo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: